BMJ  2007;335:683-684 (6 October), doi:10.1136/bmj.39346.496690.3A

Letters

Direct to consumer advertising

The world of the market place

The first 150 words of the full text of this article appear below.

Magrini and Font discuss direct to consumer advertising,1 but drug promotion at an earlier stage may have already influenced the views of the public and patients.

Current European legislation on drug promotion makes it difficult to define what promotion by a pharmaceutical company before market authorisation entails. Many drug companies employ marketing companies to promote new drugs. The recent premature promotion of Herceptin for early breast cancer is viewed as exemplary by the industry and to be copied.

Releasing early results from high profile trials at major cancer conferences can gain worldwide publicity. When supported by website press releases to inform the stock market, one sided information is freely available in the market place.

The small patient group "Women Fighting for Herceptin" was supported by a leading marketing company.2 The ensuing national media campaign pushed politicians into supporting the unlicensed use of Herceptin and hence undermined the UK Medicines Act . . . [Full text of this article]

Jonathan V Howell, consultant in public health

West Midlands Specialised Commissioning Team, Edwin House, Burton on Trent DE14 2WF

jonathan.howell@lycos.com


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to StumbleUpon StumbleUpon   Add to Technorati Technorati    What's this?

Relevant Article

Direct to consumer advertising of drugs in Europe
Nicola Magrini and Maria Font
BMJ 2007 335: 526. [Extract] [Full Text] [PDF]




Access jobs at BMJ Careers
Whats new online at Student 

BMJ